LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: The value of inquiring patients about local discomfort during blood pressure measurement for fibromyalgia detection. A cross-sectional study.

    Del-Río-Guerrero, Viridiana / Martínez-Martínez, Laura-Aline / Arias-Callejas, Karina / Carbonell-Bobadilla, Natalia / Mejía-Segura, Alejandra / Azamar-Morales, Gibran / Espinosa-Orantes, Alejandra / Molina-Sánchez, José-Raúl / Mora-Ramírez, Mauricio / Mejía-Ávila, María-Fernanda / Vargas Guerrero, Angélica / Silveira, Luis H / Martínez-Lavín, Manuel

    Seminars in arthritis and rheumatism

    2023  Volume 61, Page(s) 152218

    Abstract: Background: Fibromyalgia overlaps and/or mimics other rheumatic diseases and may be a confounding factor in the clinimetric assessment of these illnesses. Allodynia is a distinctive fibromyalgia feature that can be elicited during routine blood pressure ...

    Abstract Background: Fibromyalgia overlaps and/or mimics other rheumatic diseases and may be a confounding factor in the clinimetric assessment of these illnesses. Allodynia is a distinctive fibromyalgia feature that can be elicited during routine blood pressure measurement. For epidemiological purposes fibromyalgia can be diagnosed using the 2016 Wolfe et al. criteria questionnaire. No physical examination is required.
    Objective: To evaluate the role of a straightforward question formulated during routine blood pressure measurement for fibromyalgia detection in a rheumatology outpatient clinic.
    Patients and methods: All adult patients attending our Rheumatology outpatient clinic were invited to participate. While awaiting their medical consultation, they filled-out the 2016 Wolfe et al. FM diagnostic criteria questionnaire. During the ensuing routine physical examination, the physician advanced the following guideline: "I am going to take your blood pressure; tell me if the cuff's pressure causes pain". Then, blood pressure cuff was inflated to 170 mm/Hg. Sphygmomanometry induced allodynia was defined as any local discomfort caused by blood pressure measurement. If a patient voiced any uneasiness, a follow-up dichotomic question was formulated "did it hurt much or little". Sphygmomanometry-induced allodynia was correlated with the presence of fibromyalgia according to the 2016 Wolfe diagnostic criteria.
    Results: Four hundred and ninety-one patients were included in the study; most of them (84%) were female. The female cohort displayed the following features: Twenty five percent had fibromyalgia. Twenty seven percent had sphygmomanometry-induced allodynia. In women, sphygmomanometry-evoked allodynia had 63% sensitivity and 84% specificity for fibromyalgia diagnosis. The area under curve was 0.751. Moreover, having "much" local pain elicitation during blood pressure testing had 23% sensitivity and 96% specificity for fibromyalgia diagnosis. Men behaved differently; 15% fulfilled the fibromyalgia diagnostic criteria, but only 2% had sphygmomanometry induced allodynia.
    Conclusions: Inquiring female patients about local discomfort during routine blood pressure measurement is a simple and efficient procedure for fibromyalgia detection. This undemanding approach could be implemented in all clinical settings. There is marked sexual dimorphism in the link between sphygmomanometry-induced allodynia and fibromyalgia diagnosis. The presence of fibromyalgia is almost certain in those individuals having substantial pain elicitation during blood pressure measurement.
    MeSH term(s) Adult ; Male ; Humans ; Female ; Fibromyalgia/complications ; Fibromyalgia/diagnosis ; Cross-Sectional Studies ; Hyperalgesia/diagnosis ; Hyperalgesia/etiology ; Blood Pressure ; Pain Measurement/methods ; Pain ; Surveys and Questionnaires
    Language English
    Publishing date 2023-05-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 120247-9
    ISSN 1532-866X ; 0049-0172
    ISSN (online) 1532-866X
    ISSN 0049-0172
    DOI 10.1016/j.semarthrit.2023.152218
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.

    Maldonado, Valente / Hernandez-Ramírez, Claudia / Oliva-Pérez, Eniel Alonso / Sánchez-Martínez, César Omar / Pimentel-González, Jorge Fabián / Molina-Sánchez, José Raúl / Jiménez-Villalba, Yeimmy Zuyenn / Chávez-Alderete, Jaime / Loza-Mejía, Marco A

    International immunopharmacology

    2020  Volume 90, Page(s) 107209

    Abstract: We have previously hypothesized that pentoxifylline could be beneficial for the treatment of COVID-19 given its potential to restore the immune response equilibrium, reduce the impact of the disease on the endothelium and alveolar epithelial cells, and ... ...

    Abstract We have previously hypothesized that pentoxifylline could be beneficial for the treatment of COVID-19 given its potential to restore the immune response equilibrium, reduce the impact of the disease on the endothelium and alveolar epithelial cells, and improve the circulatory function.Serum lactate dehydrogenase (LDH) and lymphocyte count are accessible biomarkers that correlate with the severity of COVID-19, the need for hospitalization, and mortality, reflecting the host immune response's contribution to the seriousness of SARS-CoV-2 infection. We carried out this external pilot study on 38 patients with moderate and severe COVID-19 to test the effect pentoxifylline on parameters such as LDH, lymphocyte count, days of hospitalization, mortality, and proportion of patients requiring intubation. Twenty-six patients were randomized to receive 400 mg of pentoxifylline t.i.d. plus standard therapy (pentoxifylline group), while the rest received the standard treatment (control group). Linear regression models were built for statistically significant parameters. Pentoxifylline treatment was associated with a 64.25% increase (CI95% 11.83, 116.68) in lymphocyte count and a 29.61% decrease (CI95% 15.11, 44.10) in serum LDH. Although a trend towards reduced days of hospitalization, mortality, and proportion of patients requiring intubation was observed, no statistically significant difference was found for these parameters. Our findings open the possibility of pentoxifylline being repositioned as a drug for COVID-19 treatment with the advantages of a proven safety profile, availability, and no risk of immunosuppression; however, this evidence needs to be confirmed in a pragmatic randomized controlled trial.
    MeSH term(s) Aged ; Biomarkers/blood ; COVID-19/blood ; COVID-19/drug therapy ; COVID-19/immunology ; Drug Repositioning ; Female ; Humans ; L-Lactate Dehydrogenase/blood ; Lymphocyte Count ; Male ; Middle Aged ; Pentoxifylline/pharmacology ; Pentoxifylline/therapeutic use ; Pilot Projects ; SARS-CoV-2
    Chemical Substances Biomarkers ; L-Lactate Dehydrogenase (EC 1.1.1.27) ; Pentoxifylline (SD6QCT3TSU)
    Language English
    Publishing date 2020-11-26
    Publishing country Netherlands
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 2043785-7
    ISSN 1878-1705 ; 1567-5769
    ISSN (online) 1878-1705
    ISSN 1567-5769
    DOI 10.1016/j.intimp.2020.107209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top